A new study suggests that factor Xa inhibitors, such Eliquis™ apixaban from BMS and partner Pfizer, can be superior to warfarin. On a composite efficacy end-point in atrial fibrillation patients apixaban was significantly better than warfarin (1.3% versus 1.6%; p<0.01), while bleeding side-effects and death from any cause were both significantly improved, according top data from the vast 18,000 patient ARISTOTLE trial announced at the European Society for Cardiology meeting in Paris.
This is in marked contrast to the results published in the New England Journal of Medicine (365:699-708), also in August 2011, showing that apixaban increased bleeding episodes without reducing cardiovascular events in patients with acute coronary syndromes.More
The Cambridge Partnership is the only professional services company in the UK exclusively dedicated to supporting companies in the biotechnology industry. We specialize in providing a “one-stop shop” for accountancy, company secretarial, IP management and admin services. The Cambridge Partnership was founded in 2012 to fill a gap. Running a biotechnology company has little …